Drug Delivery and Translational Research

, Volume 4, Issue 2, pp 203–209

Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model

  • Ming Yang
  • Tao Yu
  • Joseph Wood
  • Ying-Ying Wang
  • Benjamin C. Tang
  • Qi Zeng
  • Brian W. Simons
  • Jie Fu
  • Chi-Mu Chuang
  • Samuel K. Lai
  • T.-C. Wu
  • Chien-Fu Hung
  • Justin Hanes
Short Communication

DOI: 10.1007/s13346-013-0190-7

Cite this article as:
Yang, M., Yu, T., Wood, J. et al. Drug Deliv. and Transl. Res. (2014) 4: 203. doi:10.1007/s13346-013-0190-7

Abstract

Intraperitoneal (IP) chemotherapy is more effective than systemic chemotherapy for treating advanced ovarian cancer, but is typically associated with severe complications due to high dose, frequent administration schedule, and use of non-biocompatible excipients/delivery vehicles. Here, we developed paclitaxel (PTX)-loaded microspheres composed of di-block copolymers of poly(ethylene glycol) and poly(sebacic acid) (PEG-PSA) for safe and sustained IP chemotherapy. PEG-PSA microspheres provided efficient loading (∼13 % w/w) and prolonged release (∼13 days) of PTX. In a murine ovarian cancer model, a single dose of IP PTX/PEG-PSA particles effectively suppressed tumor growth for more than 40 days and extended the median survival time to 75 days compared to treatments with Taxol® (47 days) or IP placebo particles (34 days). IP PTX/PEG-PSA was well tolerated with only minimal to mild inflammation. Our findings support PTX/PEG-PSA microspheres as a promising drug delivery platform for IP therapy of ovarian cancer and potentially other metastatic peritoneal cancers.

Keywords

Drug deliveryControlled releaseChemotherapyBiodegradable polymers

Supplementary material

13346_2013_190_MOESM1_ESM.doc (78 kb)
ESM 1(DOC 78.0 kb)

Copyright information

© Controlled Release Society 2014

Authors and Affiliations

  • Ming Yang
    • 1
    • 9
  • Tao Yu
    • 1
    • 9
  • Joseph Wood
    • 1
  • Ying-Ying Wang
    • 1
    • 9
  • Benjamin C. Tang
    • 2
    • 9
    • 10
  • Qi Zeng
    • 4
  • Brian W. Simons
    • 7
  • Jie Fu
    • 3
    • 9
  • Chi-Mu Chuang
    • 4
  • Samuel K. Lai
    • 2
    • 11
  • T.-C. Wu
    • 4
    • 5
    • 6
  • Chien-Fu Hung
    • 4
    • 5
    • 6
  • Justin Hanes
    • 6
    • 8
    • 9
  1. 1.Department of Biomedical EngineeringJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Chemical and Biomolecular EngineeringJohns Hopkins UniversityBaltimoreUSA
  3. 3.Department of Ophthalmology, The Wilmer Eye InstituteJohns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of PathologyJohns Hopkins University School of MedicineBaltimoreUSA
  5. 5.Department of Obstetrics and GynecologyJohns Hopkins University School of MedicineBaltimoreUSA
  6. 6.Department of Oncology, Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins University School of MedicineBaltimoreUSA
  7. 7.Department of Molecular and Comparative PathobiologyJohns Hopkins University School of MedicineBaltimoreUSA
  8. 8.Center for Cancer Nanotechnology Excellence, Institute for NanoBioTechnologyJohns Hopkins UniversityBaltimoreUSA
  9. 9.The Center for NanomedicineJohns Hopkins University School of MedicineBaltimoreUSA
  10. 10.Koch Institute for Integrated Cancer ResearchMassachusetts Institute of TechnologyCambridgeUSA
  11. 11.Eshelman School of PharmacyUniversity of North Carolina at Chapel HillChapel HillUSA